ArticleCureus2025
Evaluation and Comparison of Ketoconazole and Alkaline Glutaraldehyde Effects on Candida albicans Adherence to Three Denture Base Materials: An In Vitro Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to evaluate and compare the effects of two antimicrobial agents, ketoconazole and alkaline glutaraldehyde, on MATERIALS AND
methodsThis in vitro study was conducted at the Sibar Institute of Dental Sciences, Guntur, India, between June 2023 and June 2024. Sixty uniform wax patterns (20 × 2 mm) were fabricated and divided into three groups (n = 20 each): Group 1 (conventional heat-cured PMMA, Dental Products of India (DPI®), Mumbai, India), Group 2 (flexible denture base material, Proflex®, Prevest DenPro, Jammu, India), and Group 3 (injectable denture base material, SR Ivocap® High Impact, Ivoclar Vivadent, Schaan, Liechtenstein). Each group was subdivided into subgroups A (ketoconazole, Nizral® 2%, Johnson & Johnson, New Brunswick, NJ, USA) and B (alkaline glutaraldehyde, Hospal®-G Plus, Septodont, Saint-Maur-des-Fossés, France). The samples were inoculated with
resultsPretreatment results indicated no significant intergroup differences (p > 0.05) in CFU/mL. At 24 hours, alkaline glutaraldehyde significantly reduced
conclusionBoth ketoconazole and alkaline glutaraldehyde effectively reduced
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.